- Home
- CERO vs AQMS Comparison
CERO vs AQMS Comparison
Compare CERO & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- AQMS
- Stock Information
- Founded
- CERO 2017
- AQMS 2014
- Country
- CERO United States
- AQMS United States
- Employees
- CERO N/A
- AQMS N/A
- Industry
- CERO
- AQMS Metal Fabrications
- Sector
- CERO
- AQMS Industrials
- Exchange
- CERO Nasdaq
- AQMS Nasdaq
- Market Cap
- CERO 5.6M
- AQMS 5.1M
- IPO Year
- CERO N/A
- AQMS 2015
- Fundamental
- Price
- CERO $5.48
- AQMS $3.72
- Analyst Decision
- CERO Strong Buy
- AQMS Buy
- Analyst Count
- CERO 2
- AQMS 1
- Target Price
- CERO $45.00
- AQMS $30.00
- AVG Volume (30 Days)
- CERO 302.9K
- AQMS 30.4K
- Earning Date
- CERO 08-22-2025
- AQMS 08-13-2025
- Dividend Yield
- CERO N/A
- AQMS N/A
- EPS Growth
- CERO N/A
- AQMS N/A
- EPS
- CERO N/A
- AQMS N/A
- Revenue
- CERO N/A
- AQMS N/A
- Revenue This Year
- CERO N/A
- AQMS N/A
- Revenue Next Year
- CERO N/A
- AQMS $550.00
- P/E Ratio
- CERO N/A
- AQMS N/A
- Revenue Growth
- CERO N/A
- AQMS N/A
- 52 Week Low
- CERO $4.27
- AQMS $3.37
- 52 Week High
- CERO $895.40
- AQMS $46.00
- Technical
- Relative Strength Index (RSI)
- CERO 31.92
- AQMS 44.59
- Support Level
- CERO $4.27
- AQMS $3.59
- Resistance Level
- CERO $7.60
- AQMS $4.35
- Average True Range (ATR)
- CERO 0.54
- AQMS 0.29
- MACD
- CERO -0.22
- AQMS 0.06
- Stochastic Oscillator
- CERO 27.85
- AQMS 37.76
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.